CRISPR Therapeutics AG Share Price & Technical Analysis
CRSP · $50.36 (+0.92%)
Healthcare / Biotechnology
$50.36
+0.92%
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of t…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-2% return in May, 9% avg return in past 3 year May month.
5% return in 2026, 23% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 21% | -18% | 9% | -2% | – | – | – | – | – | – | – | 5% |
| 25 | 5% | 9% | -25% | 14% | -6% | 32% | 16% | -5% | 27% | -1% | -15% | 0% | 52% |
| 24 | 2% | 33% | -19% | -22% | 1% | -1% | 6% | -17% | -1% | -1% | 9% | -23% | -34% |
| 23 | 24% | -4% | -8% | 8% | 31% | -12% | 2% | -12% | -10% | -14% | 53% | -5% | 51% |
| 22 | -17% | -6% | 4% | -22% | 17% | 5% | 23% | -12% | 2% | -21% | 2% | -25% | -50% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.04B
P/E ratio
—
52W high
$78.48
52W low
$35.38
Volume
15,50,761
Beta
1.74
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is CRISPR Therapeutics AG share price today?
- CRISPR Therapeutics AG (CRSP) last traded around $50.36 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRSP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRSP. Download the app for real-time alerts.
- How can I analyze CRISPR Therapeutics AG stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.